INO-1001

Research use only, not for human use.

INO-1001 is a potent, selective poly(ADP-ribose) polymerase (PARP) with IC50 of <50 nM in CHO cells.

INO-1001 is a potent, selective poly(ADP-ribose) polymerase (PARP) with IC50 of <50 nM in CHO cells; significantly radiosensitizes human and rodent cell lines at 10 uM (enhancement ratios 1.4-1.6), enhances radiation-induced cell killing by interfering with DNA repair mechanisms, resulting in necrotic cell death; attenuates various aspects of the pathophysiological response in a clinically relevant experimental model of burn/smoke inhalation injury.Brain Cancer Discontinued(In Vitro):3-Aminobenzamide (PARP-IN-1) (>1 μM) causes more than 95% inhibition of PARP activity without significant cellular toxicity. INO-1001 significantly sensitizes CHO cells by blocking most of the DNA repair occurring between radiation fractions. 3-Aminobenzamide significantly improves endothelial function by enhancing the acetylcholine-induced, endothelium-dependent, nitric oxide mediated vasorelaxation after exposure with 400 μM H2O2.(In Vivo):In a db/db (Leprdb/db) mouse model, 3-Aminobenzamide ameliorates diabetes-induced albumin excretion and mesangial expansion, and also decreases diabetes-induced podocyte depletion. 3-Aminobenzamide (1.6 mg/kg via intracerebral injection) prevents NAD+ depletion and improves water maze performance after controlled cortical impact (CCI) in mice.

3-Aminobenzamide (PARP-IN-1) (>1 μM) causes more than 95% inhibition of PARP activity without significant cellular toxicity. INO-1001 significantly sensitizes CHO cells by blocking most of the DNA repair occurring between radiation fractions.?3-Aminobenzamide significantly improves endothelial function by enhancing the acetylcholine-induced, endothelium-dependent, nitric oxide mediated vasorelaxation after exposure with 400 μM H2O2.

In a db/db (Leprdb/db) mouse model, 3-Aminobenzamide ameliorates diabetes-induced albumin excretion and mesangial expansion, and also decreases diabetes-induced podocyte depletion. 3-Aminobenzamide (1.6 mg/kg via intracerebral injection) prevents NAD+ depletion and improves water maze performance after controlled cortical impact (CCI) in mice.

3-Aminobenzamide | INO1001 | INO 1001

Cell Cycle/DNA Damage

PARP

PARP

Cancer

Brain Cancer

3544-24-9

136.1512

C7H8N2O

>98% (HPLC)

10 mM in DMSO

NC(=O)C1=CC(N)=CC=C1

Benzamide, 3-amino-

(-20℃)

With Ice Pack

≥ 2 years